nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.09.2009 | Original Article

Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane

verfasst von: Sabry M. Attia, Alaa A. Al-Anteet, Nouf M. Al-Rasheed, Abdulqader A. Alhaider, Mohammed M. Al-harbi

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of the current investigation is to determine whether non-toxic doses of the catalytic topoisomerase-II inhibitor, dexrazoxane, have influence on the genomic damage induced by the anticancer topoisomerase-II poison, etoposide, on mice bone marrow cells.

Method

The scoring of micronuclei, chromosomal aberrations, and mitotic activity were undertaken as markers of cyto- and genotoxicity. Oxidative damage markers such as reduced glutathione and lipid peroxidation were assessed as a possible mechanism underlying this amelioration.

Results

Dexrazoxane pre-treatment significantly reduced the etoposide-induced micronuclei formation, chromosomal aberrations, and also the suppression of erythroblast proliferation in bone marrow cells of mice. These effects were dose dependent. Etoposide induced marked biochemical alterations characteristic of oxidative stress including enhanced lipid peroxidation and reduction in the reduced glutathione level. Prior administration of dexrazoxane ahead of etoposide challenge ameliorated these biochemical markers.

Conclusion

Based on our data presented, strategies can be developed to decrease the etoposide-induced genomic damage in normal cells using dexrazoxane.

Adler ID (1984) Cytogenetic tests in mammals. In: Venitt S, Parry JM (eds) Mutagenicity testing: a practical approach. IRL Press, Oxford, pp 275–306

Agarwal K, Mukherjee A, Sen S (1994) Etoposide (VP-16): cytogenetic studies in mice. Environ Mol Mutagen 23(3):190–193PubMedCrossRef

Andoh T, Ishida R (1998) Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1400:155–171PubMed

Ashby J, Tinwell H, Glover P et al (1994) Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella responses. Environ Mol Mutagen 24:51–60PubMedCrossRef

Attia SM (2008) Abatement by naringin of lomefloxacin-induced genomic instability in mice. Mutagenesis 23(6):515–521PubMedCrossRef

Attia SM, Kliesch U, Schriever-Schwemmer G et al (2003) Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor satellite DNA probe. Environ Mol Mutagen 41:99–103PubMedCrossRef

Attia SM, Schmid TE, Badary OA et al (2002) Molecular cytogenetic analysis in mouse sperm of chemically induced aneuploidy: studies with topoisomerase II inhibitors. Mutat Res 520:1–13PubMed

Boos G, Stopper H (2000) Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett 116(1–2):7–16PubMedCrossRef

Chen M, Beck WT (1995) Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res 55:1509–1516PubMed

10.

Choudhury RC, Palo AK, Sahu PJ (2004) Cytogenetic risk assessment of etoposide from mouse bone marrow. Appl Toxicol 24:115–122CrossRef

11.

Cierniak A, Papiez M, Kapiszewska M (2004) Modulatory effect of quercetin on DNA damage, induced by etoposide in bone marrow cells and on changes in the activity of antioxidant enzymes in rats. Rocz Akad Med Bialymst 49(Suppl. 1):167–169PubMed

12.

Drake FH, Hofmann GA, Mong SM et al (1989) In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49(10):2578–2583PubMed

13.

Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 74:214–226

14.

Felix CA (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 36(5):525–535PubMedCrossRef

15.

Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34(10):1514–1521PubMedCrossRef

16.

Hasinoff BB, Kuschak TI, Yalowich JC et al (1995) A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50:953–958PubMedCrossRef

17.

Hasinoff BB, Yalowich JC, Ling Y et al (1996) The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs 7:558–567PubMedCrossRef

18.

Hofland KF, Thougaard AV, Dejligbjerg M et al (2005) Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin Cancer Res 11(18):6722–6729PubMedCrossRef

19.

Hofland KF, Thougaard V, Sehested M et al (2005) Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Cancer Res 11:3915–3924CrossRef

20.

Holm B, Jensen PB, Sehested M (1996) ICRF-187 rescue in etoposid treatment in vivo. A model targeting high dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 38:203–209PubMedCrossRef

21.

Humeniuk R, Kaczmarek L, Peczynska-Czoch W et al (2003) Cytotoxicity and cell cycle effects of novel indolo[2, 3-b]quinoline derivatives. Oncol Res 13(5):269–277PubMed

22.

Kagan VE, Kuzmenko AI, Tyurina YY et al (2001) Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase. Cancer Res 61:7777–7784PubMed

23.

Kagan VE, Yalowich JC, Borisenko GG et al (1999) Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. Mol Pharmacol 56:494–506PubMed

24.

Kaiserová H, den Hartog GJ, Simůnek T et al (2006) Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin. Br J Pharmacol 149(7):920–930PubMedCrossRef

25.

Kapiszewska M, Cierniak A, Elas M et al (2007) Lifespan of etoposide-treated human neutrophils is affected by antioxidant ability of quercetin. Toxicol In Vitro 21(6):1020–1030PubMedCrossRef

26.

Kapiszewska M, Cierniak A, Papiez MA et al (2007) Prolonged quercetin administration diminishes the etopoide-induced DAN damage in bone marrow cells of rats. Drug Chem Toxicol 30:67–81PubMedCrossRef

27.

Langer SW, Sehested M, Jensen PB (2001) Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol 12:405–410PubMedCrossRef

28.

Lebrecht D, Geist A, Ketelsen UP et al (2007) Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 151(6):771–778PubMedCrossRef

29.

Lowry OM, Rosebrough NJ, Fare AL et al (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193:265–275PubMed

30.

Minotti G, Menna P, Salvatorelli E et al (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229PubMedCrossRef

31.

Mo YY, Beck WT (1999) DNA damage signals induction of Fas ligand in tumor cells. Mol Pharmacol 55:216–222PubMed

32.

Ohkawa H, Ohishi N, Yagi K (1979) Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRef

33.

Pearlman M, Jendiroba D, Pagliaro L et al (2003) Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leuk Res 27:617–626PubMedCrossRef

34.

Pearlman M, Jendiroba D, Pagliaro L et al (2003) Dexrazoxane’s protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity. Cancer Chemother Pharmacol 52:477–481PubMedCrossRef

35.

Ritov VB, Goldman R, Stoyanovsky DA et al (1995) Antioxidant paradoxes of phenolic compounds: peroxyl radical scavenger and lipid antioxidant, etoposide (VP-16), inhibits sarcoplasmic reticulum Ca(2+)-ATPase via thiol oxidation by its phenoxyl radical. Arch Biochem Biophys 321:140–152PubMedCrossRef

36.

Sehested M, Jensen PB, Sørensen BS et al (1993) Antagonistic effect of the cardioprotector (+)-1, 2-bis(3, 5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46(3):389–393PubMedCrossRef

37.

Siitonen T, Alaruikka P, Mantymaa P et al (1999) Protection of acute myeloblastic leukemia cells against apoptotic cell death by high glutathione and gamma-glutamylcysteine synthetase levels during etoposide-induced oxidative stress. Ann Oncol 10:1361–1367PubMedCrossRef

38.

Smith PJ, Soués S, Gottlieb T et al (1994) Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. Br J Cancer 70:914–921PubMed

39.

Swain SM, Vici P (2004) The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 130:1–7PubMedCrossRef

40.

Swain SM, Whaley F, Gerber MC et al (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333–1340PubMed

41.

Topcu Z (2001) DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 26:405–416PubMedCrossRef

42.

Turner SD, Wijnhoven SW, Tinwell H et al (2001) Assays to predict the genotoxicity of the chromosomal mutagen etoposide-focussing on the best assay. Mutat Res 493(1–2):139–147PubMed

43.

Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635–692PubMedCrossRef

44.

Wang L, Eastmond DA (2002) Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187. Environ Mol Mutagen 39(4):348–356PubMedCrossRef

45.

Zima T, Tesar V, Crkovská J et al (1998) ICRF-187 (dexrazoxan) protects from adriamycin-induced nephrotic syndrome in rats. Nephrol Dial Transplant 13(8):1975–1979PubMedCrossRef

Titel: Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane
verfasst von: Sabry M. Attia
Alaa A. Al-Anteet
Nouf M. Al-Rasheed
Abdulqader A. Alhaider
Mohammed M. Al-harbi
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-0934-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane

Abstract

Purpose

Method

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer

The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

MTT assays can underestimate cell numbers

Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie